I knew I was kind of a guinea pig, but the only other option was staying at home, and I wasn’t going to make it,” Tim Story ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the ...

For patients with distant-stage cancers, there was an increase in early palliative care (PC) billing from 2010 to 201 ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolic ...

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line ...

Philip Bergman, DVM, MS, PhD, DACVIM (Oncology), kicked off the 2025 Fetch Charlotte conference with his keynote address on ...

Elizabeth K. Lee, MD, a medical oncologist in the gynecologic oncology program at Dana-Farber, presented results from a phase ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Iowa lawmakers are pushing to regulate tanning beds and add more supervision when minors use them. According to the National Cancer Institute, more than half of the new cancers among adolescents ...